Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
21-40 of 653 trials

Multiple Sclerosis: Rituximab vs. Ocrelizumab Study

We are comparing two treatments for relapsing-remitting multiple sclerosis to see if rituximab is as effective as ocrelizumab in preventing disease activity. This study also examines patient quality of life and other important factors.

Multiple Sclerosis1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesNeurology

Migraine Prevention: Atogepant for Kids

We are studying the long-term safety and tolerability of atogepant in children and teens aged 6 to 17 with migraines. This research aims to ensure the treatment is safe for young patients.

Migraine1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Ulcerative Colitis: GS-5290 Medication Study

We are testing a new medication for people with moderately to severely active ulcerative colitis to see if it helps improve symptoms better than a placebo. The study will assess various measures of clinical response and remission.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Migraine Relief: High-Flow Oxygen Therapy

We are studying whether high-flow oxygen therapy can help relieve migraine attacks in the emergency department. The trial also looks at its effects on related symptoms and overall patient experience.

Common Migraine1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNeurology

Primary Membranous Nephropathy: Zanubrutinib vs. Tacrolimus

We are studying whether zanubrutinib can reduce protein levels in urine and lead to remission in patients with primary membranous nephropathy compared to tacrolimus. This trial aims to evaluate the safety and effectiveness of both treatments.

Primary Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNephrology

Brexucabtagene Autoleucel for Rare B-cell Malignancies

We are studying a new treatment for adults with relapsed or refractory Richter Transformation of B-cell malignancies. The goal is to see if it improves response rates and overall survival compared to existing options.

Relapsed/Refractory Richter Transformation1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Sodium Bicarbonate for Cardiac Arrest Treatment

We are studying whether sodium bicarbonate can help patients regain heart function during in-hospital cardiac arrest. The trial also looks at its effects on survival and neurological outcomes after 30 days.

In-Hospital Cardiac Arrest1-2 yearsMonitoring phase (IV)Standard MedicinesCardiology

Colorectal Cancer: UNICORN Study on Targeted Preoperative Treatments

We are studying short-course targeted treatments for patients with resectable colorectal cancer to see if they improve treatment response and quality of life. This trial aims to understand the safety and effectiveness of these treatments before surgery.

Colorectal Adenocarcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Atrial Fibrillation: Semaglutide for Weight Control

We are studying whether a weekly injection of semaglutide helps people with obesity and atrial fibrillation achieve a normal heart rhythm. The trial also looks at how weight loss affects symptoms and quality of life.

ObesityAtrial Fibrillation1-2 yearsMonitoring phase (IV)≤5 visitsInvestigational MedicinesCardiologyEndocrinologyInternal Medicine

Triple-Negative Breast Cancer: PLX038 Treatment Study

We are studying the effects of PLX038 in patients with locally advanced or metastatic triple-negative breast cancer. The goal is to see how well it works and to understand its safety and tolerability.

Advanced Triple-Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Fertility Treatment: Progesterone Support in IUI

We are studying if adding progesterone support helps couples with unexplained infertility achieve higher live birth rates during intra-uterine insemination. We also want to see if this approach is cost-effective and safe.

Female Infertility and Subfertility1-2 yearsMonitoring phase (IV)Investigational MedicinesEndocrinologyGynecology and Obstetrics

High-Risk Prostate Cancer: THUNDER Trial

We are studying new diagnostic tracers and treatment options for men with high-risk prostate cancer. The goal is to see if these methods improve survival and quality of life compared to standard treatments.

Prostate Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesOncologyUrology

Richter Syndrome: GLOfitamab with Chemotherapy

We are studying a new treatment combining GLOfitamab with standard chemotherapy for patients with Richter syndrome. The goal is to see if this combination improves treatment response and safety.

Richter's Syndrome1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Graft-Versus-Host Disease: Anti-Lymphocyte Serum Study

We are studying how the anti-lymphocyte serum works in children and adults receiving stem cell transplants. This research aims to improve prevention strategies for graft-versus-host disease.

Stem Cell Transplant1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHematologyPediatrics

Staphylococcal Joint Infection: Rifampicin vs. Clindamycin

We are studying whether a targeted antibiotic can effectively treat staphylococcal infections in joint prostheses compared to a traditional combination therapy. This trial also examines quality of life and any side effects experienced by participants.

Prosthetic Joint Infection1-2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesInfectious DiseasesOrthopedics and Traumatology

Brain Tumor Treatment: BI 764532 Dosing Study

We are testing how well different doses of BI 764532 are tolerated by people with brain tumors that are positive for DLL3. This study aims to ensure the safety of the medication for future use.

Glioma1-2 yearsSafety phase (I)NeurologyOncology

Metreleptin for Young Children with Generalized Lipodystrophy

We are studying whether metreleptin can help children under 6 years old with generalized lipodystrophy and related diabetes. The trial will also look at its effects on quality of life and other health markers.

Generalized Lipodystrophy1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteDermatologyEndocrinology

Leukemia and Lymphoma: Dasatinib and Venetoclax Study for Children

We are testing two new drugs for children with relapsed or refractory leukemia or lymphoma that have specific genetic mutations. The goal is to assess safety and see if these drugs can effectively treat their condition.

Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Polymyalgia Rheumatica: Secukinumab Injection Study

We are studying whether secukinumab, combined with a glucocorticoid taper, can help patients with polymyalgia rheumatica achieve better remission compared to a placebo. This trial also looks at the safety and quality of life for participants.

Polymyalgia Rheumatica1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Inclusion Body Myositis: ABC008 Treatment Study

We are studying the safety and effectiveness of a new treatment called ABC008 for people with Inclusion Body Myositis. The goal is to see if it improves muscle function and strength compared to a placebo.

Inclusion Body Myositis1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyRheumatology